- Home
- AUST vs ACHL Comparison
AUST vs ACHL Comparison
Compare AUST & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- ACHL
- Stock Information
- Founded
- AUST 2020
- ACHL 2016
- Country
- AUST Canada
- ACHL United Kingdom
- Employees
- AUST N/A
- ACHL N/A
- Industry
- AUST
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AUST
- ACHL Health Care
- Exchange
- AUST Nasdaq
- ACHL Nasdaq
- Market Cap
- AUST 39.0M
- ACHL 40.4M
- IPO Year
- AUST 2022
- ACHL 2021
- Fundamental
- Price
- AUST $1.78
- ACHL $1.07
- Analyst Decision
- AUST
- ACHL Hold
- Analyst Count
- AUST 0
- ACHL 3
- Target Price
- AUST N/A
- ACHL $2.83
- AVG Volume (30 Days)
- AUST 436.2K
- ACHL 126.9K
- Earning Date
- AUST 11-06-2024
- ACHL 11-14-2024
- Dividend Yield
- AUST N/A
- ACHL N/A
- EPS Growth
- AUST N/A
- ACHL N/A
- EPS
- AUST N/A
- ACHL N/A
- Revenue
- AUST N/A
- ACHL N/A
- Revenue This Year
- AUST N/A
- ACHL N/A
- Revenue Next Year
- AUST N/A
- ACHL N/A
- P/E Ratio
- AUST N/A
- ACHL N/A
- Revenue Growth
- AUST N/A
- ACHL N/A
- 52 Week Low
- AUST $0.62
- ACHL $0.63
- 52 Week High
- AUST $3.19
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- AUST 41.88
- ACHL 65.39
- Support Level
- AUST $2.23
- ACHL $0.99
- Resistance Level
- AUST $2.42
- ACHL $1.07
- Average True Range (ATR)
- AUST 0.35
- ACHL 0.04
- MACD
- AUST -0.14
- ACHL -0.00
- Stochastic Oscillator
- AUST 1.05
- ACHL 80.31
About AUST Austin Gold Corp.
Austin Gold Corp is a gold exploration and development company focused on gold targets and making district-scale gold discoveries in Nevada. Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Fourmile Basin in Nye County.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.